columns_onemed_logo.jpg
www.onemedplace.com

OneMedPlace (OMP) is a New York based healthcare research and media company that manages a business development platform to help emerging healthcare and life sciences companies maximize their potential. OMP offers an innovative and powerful suite of services to globally connect investors and strategic partners to the companies shaping the future of health and medicine. OMP provides to strategic and financial investors efficient access to information about high potential opportunities around the world the thorough an integrated set of tools.

Pdf

AVI Biopharma’s Chief Science Officer To Resign

13th Apr 2012, 12:01 pm

Drug developer AVI Biopharma Inc. said Thursday that Chief Scientific Officer Peter Linsley will resign from the company on June 1.

AVI did not disclose a reason for Linsley’s departure or name a replacement.

AVI Biopharma is a development stage company, and it has no products on the market. On April 2 the company said its most advanced drug candidate, the experimental muscular dystrophy treatment eteplirsen, met its main goal in a mid-stage clinical trial. Patients who took eteplirsen had a significant increase in the protein that strengthens skeletal muscle. However the drug did not help patients walk, and AVI shares fell 27.9 percent, from $1.54 to $1.11.

The stock rose 3 cents, or 2.8 percent, to close at $1.10. It lost 6 cents, or 5.5 percent, to $1.04 in after-hours trading.

See the company’s SEC filing here.

MEDIA ENCLOSURE: http://www.onemedplace.com/blog/wp-content/uploads/2012/04/resignation.jpg



Register here to be notified of future One Med Place articles.
Connect with Facebook to view or add comments for this article
Proactiveinvestors recommends